Immunological Disorders and Immunotherapy
Open Access
ISSN: 2593-8509
+44-77-2385-9429
ISSN: 2593-8509
+44-77-2385-9429
Yehia Mohamed
Ajman University, UAE
Scientific Tracks Abstracts: IDIT
Sub-Saharan Africa carries the biggest burden of the human immunodefi ciency virus type 1 (HIV-1)/AIDS epidemic and is in an urgent need of an effective vaccine. CD8+ T cells are an important component of the host immune response to HIV-1 and may need to be harnessed if a vaccine is to be effective. CD8+ T cells recognize human leukocyte antigen (HLA)-associated viral epitopes and the HLA alleles vary signifi cantly among different ethnic groups. It follows that defi nition of HIV-1-derived peptides recognized by CD8+ T cells in the geographically relevant regions will critically guide vaccine development. Here, we study fi ne details of CD8+ T-cell responses elicited in HIV-1/2-uninfected individuals in Nairobi, Kenya, who received a candidate vaccine delivering conserved regions of HIV-1 proteins called HIVconsv. Using 10-day cell lines established by in vitro peptide restimulation of cryopreserved PBMC and stably HLA-transfected 721.221/ C1R cell lines, we confi rm experimentally many already defi ned epitopes, for a number of epitopes we defi ne the restricting HLA molecule’s and describe four novel HLA-epitope pairs. We also identify specifi c dominance patterns, a promiscuous T-cell epitope and a rescue of suboptimal T-cell epitope induction in vivo by its functional variant, which all together inform vaccine design.
Yehia Mohamed currently working as an Assistant Professor in the Department of Immunology at Ajman University, UAE. He received his undergraduate degree from Al-Azhar University in Cairo, Egypt. His phd was awarded in the Department of Infection, Immunity, and Infl ammation, College of Medicine and Biological Sciences at Leicester University, UK. Yehia Mohamed has a variety of research interests including immunotherapeutic management of malignant tumors, especially hematologic malignancies, vaccine development for chronic viral infections and immunomodulatory effects of the newly introduced therapeutic medications.